Please assess the completion status of the following clinical trial:

Trial Title: Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with type 1 diabetes mellitus: Fasting c-peptide \< 0.1nmol/l on insulin therapy for more than 12 months with or without history of diabetic ketoacidosis and treatment with liraglutide at maximal tolerated doses for at least 6 months prior to start of the study.~* Willing to use a continuous glucose monitoring device (CGM) and regularly measuring their blood sugars four times daily~* HbA1c of less than or equal to 11%.~* Well versed with carbohydrate counting~* Age 18-75 years~Exclusion Criteria:~* Type 1 diabetes for less than 12 months.~* Coronary event or procedure (myocardial infarction, unstable angina, coronary artery bypass, surgery or coronary angioplasty) in the previous four weeks~* Hepatic disease (transaminase \> 3 times normal) or cirrhosis~* ESRD on hemodialysis; and or e-GFR less than 30 ml/min/1.73m2~* HIV or Hepatitis C positive status~* Participation in any other concurrent clinical trial~* Any other life-threatening, non-cardiac disease~* Use of an investigational agent or therapeutic regimen within 30 days of study~* History of pancreatitis~* Pregnancy~* Inability to give informed consent~* History of gastroparesis~* History of medullary thyroid carcinoma or MEN 2 syndrome~* Family history of MEN 2, Family history of medullary thyroid cancer, or familial medullary thyroid cancer~* Women of childbearing potential who are not using adequate contraception~* Women who are pregnant~* History of serious hypersensitivity reaction to these agents.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): 12 weeks of treatment with Insulin, Liraglutide and Dapagliflozin Placebo
- Active drugs (Type: ACTIVE_COMPARATOR): 12 weeks of treatment with Insulin, Liraglutide and Active Dapagliflozin Drug

Based on this trial design, predict the completion outcome and termination type (if applicable).